SunWay Biotech Co., Ltd. announced on the 18th that it held a strategic alliance signing ceremony and product launch event with Gnosis by Lesaffre, a subsidiary of Lesaffre Group, the world's largest fermentation raw material manufacturer. In addition to forming a long-term partnership, they also collaborated on their first innovative product, "MenaQ7 Metabolic," targeting the $2 billion global market opportunity.
SunWay Biotech stated that Gnosis by Lesaffre, a wholly-owned subsidiary of Lesaffre Group, is the world's largest fermentation solution provider with nearly 170 years of proven history. It focuses on nutrition, health, and personal care businesses and demonstrates how to improve life by exploring, capturing, and cultivating the unique power of microorganisms through the application of innovative active molecules.
Gnosis by Lesaffre not only has its headquarters in France but also operates in major markets globally, including the United States, Switzerland, Italy, India, and mainland China. It has established a complete and real-time customer relationship network in key locations worldwide, efficiently delivering a variety of health and nutrition solutions to every corner of the world.
The collaboration between SunWay Biotech and Gnosis by Lesaffre announced this time, "MenaQ7 Metabolic," integrates SunWay's unique ANKASCIN 568-R and Gnosis by Lesaffre's patented MenaQ7. MenaQ7 is the only MK-7 form clinically proven to benefit bone and heart health. It provides the highest quality commitment and remains the natural choice for stable and protected vitamin K2, even after undergoing strict processing conditions for terminal supplements and food.
SunWay Biotech's ANKASCIN 568-R is the world's only red yeast fermentation raw material without Monacolin K (Statin). This industry-leading development achievement has not only led SunWay Biotech to be invited by the United States Pharmacopeia (USP) to assist in formulating the red yeast supplement chapter but also obtained New Dietary Ingredient (NDI) qualification certification.
SunWay Biotech stated that ANKASCIN 568-R has published over 130 scientific literature proving that the ingredient can solve various metabolic problems through anti-glycation and anti-atherosclerosis effects. It has been nominated for the Nutraingredient US/Europe Awards for consecutive years and won the "Best Herbal Product of the Year" at the Nutraingredient Asia Awards in 2023. Most importantly, it has successfully helped customers' end products to dominate the sales market in Taiwan for many years.
Chia-Yueh Pan, General Manager of SunWay Biotech, expressed that the company develops products based on scientific evidence in the fermentation field and continuously optimizes and innovates core fermentation technology through systematic expansion of strain libraries to maintain a leading competitive advantage in technology, processes, and cost-effectiveness. He is delighted to cooperate strategically with Gnosis by Lesaffre to jointly create uniquely differentiated raw material products for the global health and nutrition industry, providing higher quality and more diverse raw material applications for developers.
With the start of this new partnership, SunWay Biotech and Gnosis by Lesaffre will accelerate their expansion in multiple regions such as the United States and Asia. This strategic alliance is SunWay Biotech's first cross-border business expansion plan announced since formally joining the Perrigo Group in November last year. SunWay Biotech will further leverage this opportunity and experience from the collaboration to actively promote more product innovations and excellent business models in the international market.
Resource: 晨暉生技攜手全球最大發酵原料集團 強攻全球市場
